NASDAQ · GLSI
Greenwich LifeSciences, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for GLSI: Nov 13, 2026
Greenwich LifeSciences, Inc. Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.3. The reported EPS for the same quarter last year was $-0.3.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.30 | $-0.30 | $-0.30 | 1 |
| Dec 2026 | $-0.30 | $-0.30 | $-0.30 | 1 |
| Mar 2027 | $-0.30 | $-0.30 | $-0.30 | 1 |
| Jun 2027 | $-0.29 | $-0.29 | $-0.29 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · RTTNews- BNK Invest · Oct 13, 1:45 PM EDTTuesday Sector Laggards: Biotechnology, Metals & Mining StocksIn trading on Tuesday, biotechnology shares were relative laggards, down on the day by about 3%. Helping drag down the group were shares of Syndax Pharmaceuticals, off about 17% and shares of Greenwich LifeSciences off about 16.1% on the day. Also lagging the market Tuesday ar
- RTTNews · Aug 20, 10:38 PM EDTAfter-hours Gainers: HOWL Jumps 90%, MODD To Begin Pivot Pump Rollout, BIVI Awaits Long COVID Data(RTTNews) – The SPDR S&P Biotech ETF (XBI), a broad benchmark for the U.S. biotech sector, fell 3.64% during regular trading Thursday but edged 0.21% higher in after-hours trading. Among the notable biotech gainers in after-hours trading were Werewolf Therapeutics, which is advan
- RTTNews · Jul 20, 9:56 AM EDTGreenwich Advances FLAMINGO-01 Phase III Trial With Strategic Enrollment Changes(RTTNews) – Greenwich LifeSciences, Inc. (GLSI),a clinical-stage biopharmaceutical company, has provided new clinical updates on its pivotal Phase III trial, FLAMINGO-01, evaluating GLSI-100, an immunotherapy for treating breast cancer recurrences.
- BNK Invest · Jul 17, 4:36 PM EDTGreenwich LifeSciences Becomes Oversold (GLSI)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- RTTNews · Jul 9, 7:33 AM EDTGreenwich Secures European Approval For Use Of Commercially Manufactured GP2 In FLAMINGO-01(RTTNews) – Greenwich LifeSciences, Inc. (GLSI), a clinical-stage biopharmaceutical company, announced that the European Medicines Agency (EMA) has approved the use of its commercially manufactured GP2 immunotherapy in the ongoing Phase III FLAMINGO-01 trial for breast cancer rec
- RTTNews · Jun 5, 10:26 AM EDTWeekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN(RTTNews) – This week, the biotech sector saw a wave of regulatory approvals in the U.S., alongside study halts, strategic collaborations, acquisitions, deal closures, and encouraging data readouts. Positive clinical study data readouts spanned multiple therapeutic areas, inclu
- BNK Invest · Jun 2, 12:01 PM EDTTuesday Sector Laggards: Application Software, Biotechnology StocksIn trading on Tuesday, application software shares were relative laggards, down on the day by about 3%. Helping drag down the group were shares of ODDITY Tech, down about 30.3% and shares of Verra Mobility down about 15.9% on the day. Also lagging the market Tuesday are biotec
- RTTNews · Jun 1, 10:51 AM EDTGreenwich Presents Positive Phase 3 FLAMINGO-01 Data For GLSI-100 In Breast Cancer(RTTNews) – Greenwich LifeSciences Inc. (GLSI), a clinical-stage biopharmaceutical company, on Monday released positive Phase 3 FLAMINGO-01 data for GLSI-100 in preventing breast cancer recurrences. The data was presented at the annual meeting of the American Association of Clini
- RTTNews · Apr 20, 7:24 AM EDTGreenwich LifeSciences Highlights Phase III FLAMINGO-01 Data At AACR 2026(RTTNews) – Greenwich LifeSciences, Inc. (GLSI) presented new open-label data from its pivotal Phase III FLAMINGO-01 trial of GLSI-100, an immunotherapy designed to prevent breast cancer recurrences, at the AACR Annual Meeting 2026 in San Diego.
- RTTNews · Mar 17, 7:04 AM EDTGreenwich LifeSciences Reports 83% Drop In Breast Cancer Recurrence; Stock Up(RTTNews) – Greenwich LifeSciences, Inc. (GLSI) has shared promising new data from its Phase 3 FLAMINGO-01 trial, showing that breast cancer recurrence rates in one arm of the study has dropped to less than 1% per year- a major step forward for its immunotherapy candidate, GLSI-1
- RTTNews · Mar 3, 7:14 AM ESTGreenwich LifeSciences Boosts Patient Screening In FLAMINGO-01 Breast Cancer Trial(RTTNews) – Greenwich LifeSciences, Inc. (GLSI) announced that patient screening in its pivotal Phase 3 trial, FLAMINGO-01, has accelerated to more than 800 patients per year, marking a 33% increase over the prior rates. The study is evaluating GLSI-100, an immunotherapy designed
- RTTNews · Jan 25, 11:08 PM ESTAfter-Hours Gainers: Biotech Stocks In Focus(RTTNews) – Biotech shares saw strong moves in Friday's after-hours session, with Sarepta leading on upcoming trial data and several peers advancing on recent clinical and regulatory updates.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Greenwich LifeSciences, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.